Evotec is collaborating with Active Biotech to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.
Evotec will use its expertise and technologies in assay development, high-throughout screening (HTS) and surface plasmon resonance (SPR) screening for the identification and validation of novel hits.
In order to maximise the probability of finding high-quality medicinal chemistry starting points, Evotec will screen its Lead Discovery Library, a small molecule collection designed for diversity, novelty and quality.
